Merck (MRK): VA awarded $23K

$23K

committed so far

Signed

May 8, 2026

Updated

May 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 4, 2026CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
3. Mar 27, 2026CongressDisclosed sale of MRK — reported range $15,001 - $50,000
4. Apr 15, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
5. Apr 24, 2026FDAFDA drug approval: Keytruda Qlex
6. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
7. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
8. May 4, 2026Federal contract · $43K obligatedDepartment of Veterans Affairs awarded Merck: $43K obligated to date
9. May 8, 2026 · this disclosureFederal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date

What came next

1. May 11, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
2. May 11, 2026Federal contract · $342K obligatedDepartment of Veterans Affairs awarded Merck: $342K obligated to date
3. May 21, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
4. Jun 12, 2026FDAFDA drug approval: Welireg
5. Jun 12, 2026FDAFDA drug approval: Keytruda
6. Jun 12, 2026FDAFDA drug approval: Keytruda Qlex
7. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
8. Jun 12, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
9. Jun 23, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
10. Jun 24, 2026FDAFDA drug approval: Keytruda
11. Jun 24, 2026FDAFDA drug approval: Keytruda Qlex
12. Jul 10, 2026FDAFDA drug approval: Keytruda
13. Jul 10, 2026FDAFDA drug approval: Keytruda Qlex
14. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
15. Aug 5, 2026Insider · 2 peopleInsiders: 6 sales (~$9.2M)
16. Aug 6, 2026Insider · 2 peopleInsiders: 4 sales (~$2.8M)
17. Aug 10, 2026InsiderOfficer sold ~$2.71M of MRK shares in the open market
18. Aug 11, 2026Insider · 1 personInsiders: 2 sales (~$1.7M)
19. Aug 12, 2026Insider · 2 peopleInsiders: 3 sales (~$12.3M)
20. Aug 13, 2026InsiderOfficer sold ~$1.35M of MRK shares in the open market

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Merck

• SEC Form 144Nov 12, 2026
• SEC Form 144Nov 2, 2026
• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026

Everything OQRO holds on this company is on its MRK page.